Evidence map›Paper›PMID 41741599›Full record

ArticleScientific reports2026

Magnetic molecularly imprinted polymer coated with chitosan shell for enhanced controlled drug release.

Najva Sadri, Mohammad Mazloum-Ardakani, Yvonne Joseph, Parvaneh Rahimi

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Najva SadriDepartment of Chemistry, Faculty of Science, Yazd University, Yazd, 89195- 741, Islamic Republic of Iran.
Mohammad Mazloum-ArdakaniDepartment of Chemistry, Faculty of Science, Yazd University, Yazd, 89195- 741, Islamic Republic of Iran. mazloum@yazd.ac.ir.
Yvonne JosephInstitute of Nanoscale and Biobased Materials, Faculty of Materials Science and Technology, Technische Universität Bergakademie Freiberg, 09599, Freiberg, Germany.
Parvaneh RahimiInstitute of Nanoscale and Biobased Materials, Faculty of Materials Science and Technology, Technische Universität Bergakademie Freiberg, 09599, Freiberg, Germany. Parvaneh.Rahimi@esm.tu-freiberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A pH-responsive chitosan-coated magnetic molecularly imprinted polymer (MMIP) was developed as a controlled-release drug carrier with enhanced selectivity, loading capacity, and release modulation. The carrier was constructed by synthesizing Fe3O4@SiO2 magnetic cores and forming a molecularly imprinted shell using 3-aminopropyltriethoxysilane (APTES) as the functional monomer. Imatinib (IMA), a clinically important tyrosine kinase inhibitor, was used as both the model drug and the template to evaluate the carrier’s performance. To further enhance sustained and pH-responsive release, the MMIP was coated with a biocompatible chitosan (CS) layer after drug loading, yielding a hybrid core–shell nanocomposite (MMIP@CS). Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD), vibrating sample magnetometry (VSM), microscopic images and dynamic light scattering (DLS) confirmed its structural integrity, magnetic properties, and well-controlled synthesis process. The system exhibited a high drug loading capacity (65.4%), reflecting strong molecular recognition within the imprinted cavities. The release studies at pH 7.4 and 5.5 demonstrated that the CS coating significantly improved release control over 96 h compared to the uncoated MMIP, enabling sustained and pH-dependent drug delivery. Kinetic modeling indicated that the Korsmeyer–Peppas model best described the release mechanism, suggesting a combined diffusion- and polymer-relaxation-controlled process. In vitro cytotoxicity assays further confirmed that IMA-MMIP@CS exhibited enhanced cytotoxicity against K562 cells while maintaining higher viability in normal PBMCs, highlighting its biocompatibility and therapeutic potential.

Indexed as

ChitosanDrug CarriersMolecular ImprintingMolecularly Imprinted PolymersDelayed-Action PreparationsDrug LiberationHumansHydrogen-Ion ConcentrationImatinib MesylateNanocompositesPropylaminesSilanesSpectroscopy, Fourier Transform InfraredX-Ray Diffractionamino-propyl-triethoxysilaneChitosanDelayed-Action PreparationsDrug CarriersImatinib MesylateMolecularly Imprinted PolymersPropylaminesSilanesChitosanControlled releaseDrug deliveryMagnetic molecularly imprinted polymerpH-sensitive system

Identifiers

PMID41741599
PMCPMC13043948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.